Efficacy and Safety of Subcutaneous Ustekinumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis: Results of the Open-label, Phase 3 PSUMMIT-Jr Study Through Week 52 (ACR Convergence 2026) - Sep 8, 2026 - Abstract #1505; Pres time: Nov 9, 2026; 10:30 AM - 12:30 PM; Location: WB1&2; In Person; No abstract available
Clinical • P3 data • Idiopathic Arthritis • Immunology • Inflammatory Arthritis • Pediatrics • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies
|
|
Hermine Brunner, MD, MSc, MBA
|